UMB Bank’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.5K Hold
685
– – ﹤0.01% 1888
2026
Q2
$12.5K Hold
685
– – ﹤0.01% 1863
2026
Q1
$9.7K Hold
685
– – ﹤0.01% 1863
2025
Q4
$7.09K Buy
+685
New +$6.18K ﹤0.01% 1933

Other funds holding CGEM

UMB Bank's CGEM Position: Q3 2026 in Review

UMB Bank held its Cullinan Therapeutics (CGEM) position steady in Q3 2026 at 685 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1888.

UMB Bank first reported a position in CGEM in Q4 2025 and has held it in 4 quarters since. The position peaked at $12.5K in Q2 2026. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • UMB Bank held 685 shares of Cullinan Therapeutics worth $10.5K as of Q3 2026.
  • UMB Bank left its Cullinan Therapeutics share count unchanged in Q3 2026.
  • Cullinan Therapeutics made up ﹤0.01% of UMB Bank's portfolio in Q3 2026, its #1888 holding.
  • UMB Bank first reported a position in Cullinan Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • UMB Bank's Cullinan Therapeutics position peaked at $12.5K in Q2 2026.
  • 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on UMB Bank's 13F filing for Q3 2026, filed 6 Nov 2026.